The Pharma Data

FEBRUARY 5, 2021

CoolSculpting ® has been an industry-leader, creating the market for non-invasive fat reduction over 10 years ago. American Society for Dermatologic Surgery (ASDS) consumer survey on cosmetic dermatologic procedures 2018 available at [link]. “The number one aesthetic concern for consumers is excess body fat 1.

Dermatology 52

Dermatology Cosmetics Allergies Production 52

The Pharma Data

MARCH 27, 2022

These 52-week pooled analyses demonstrate continued improvement in scalp, eyebrows and eyelash hair regrowth from 36-week results published today in the New England Journal of Medicine and presented at the 2021 European Academy of Dermatology and Venereology (EADV) Congress. In February 2022, the U.S. ” About OLUMIANT®.

Dermatology 40

Dermatology Medicine Licensing Licensing 40

The Pharma Data

FEBRUARY 25, 2022

Food and Drug Administration (FDA) has accepted for review the Prior Approval Supplement (PAS) to the Biologics License Application (BLA) for ABRILADA™ (adalimumab-afzb) as an interchangeable biosimilar to Humira® (adalimumab). Pfizer Inc. NYSE: PFE) today announced that the U.S.

FDA Approval 52

FDA Approval Production Medicine Dermatology 52

pharmaphorum

JUNE 2, 2021

The deal gives Amgen rights to the KHK4083 antibody in all countries except Kyowa’s home market of Japan, and is back-loaded with potential milestone payments worth another $850 million plus royalties on sales. Kyowa will co-promote the drug in the US if approved, with opt-in rights in some other countries as well.

Drugs 52

Drugs Licensing Licensing Sales 52

Druggist

DECEMBER 9, 2020

Clobetasone has a narrow licensed use. Dactacort has also antibacterial properties and is one of few over the counter creams licensed for bacterial infections. An interesting licensed use for Eurax cream is the treatment of scabies and itchy skin infestation in the skin. E45 Dermatological Itch Relief Cream, 100g.

Pharmacy 97

Pharmacy Containment Sales Production 97

pharmaphorum

APRIL 26, 2021

Merck licensed sonelokimab (M1095) from Ablynx in 2013, and four years later formed a partnership with Avillion to carry out phase 2 and 3 testing of the drug. There are plenty of other biologics available for psoriasis however, and Avillion and Merck will need stellar data to differentiate their drug in the market.

Antibody 52

Antibody Drugs Marketing Licensing 52

The Pharma Data

AUGUST 17, 2021

The company recently announced Breakthrough Therapy designation for donanemab and its intention to submit a biologics license application (BLA) under the accelerated approval pathway later this year. Prior to joining Loxo Oncology, Van Naarden served in various biotechnology investment, operations and advisory roles. except for Canada.

Medicine 52

Medicine Dermatology Production Development 52

pharmaphorum

MAY 25, 2022

The main problem is that the market for psoriasis therapies is very crowded – so much so that Eli Lilly abandoned plans to launch its antibody therapy mirikizumab for the skin disease and is focusing instead on inflammatory bowel disease. It’s also in clinical testing for atopic dermatitis or eczema, with results due next year.

Drugs 52

Drugs FDA Approval Licensing Licensing 52

The Pharma Data

JANUARY 13, 2021

(IPIX) is a clinical stage biopharmaceutical company developing a world-class portfolio of innovative therapies addressing multiple areas of unmet medical need, including inflammatory diseases, cancer, infectious diseases, and dermatologic diseases. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A.

Clinical Trials 52

Clinical Trials Clinical Trials Trials In-Vitro 52

The Pharma Data

JANUARY 12, 2021

Virology, Respiratory, Dermatology, Allergy, & Rheumatology) in early & late stage Clinical Development and in Medical Affairs, with a strong track record for Developing and Accelerating Phase I–IV programs. He has in depth Global Development Expertise (e.g. Previously, he held roles as CMO at Trimeris Inc.

Life Science 52

Life Science Antibody In-Vivo In-Vitro 52

Roots Analysis

JANUARY 3, 2024

Moreover, at present, women dominate the medical aesthetics industry with over 90% market share. All these innovations are crucial to drive the growth of breast implants market. Increased awareness among people and a higher number of licensed medical professionals can help in driving the future of this market.

Filler 40

Filler Cosmetics Production Dermatology 40

The Pharma Data

NOVEMBER 4, 2020

Initial data from an ongoing long-term, open label extension study with CTP-543 were presented in the late-breaking news session at the European Academy of Dermatology and Venereology (EADV) Virtual Congress on October 29, 2020. Published Findings on Alopecia Areata Burden of Disease in Journal of Investigative Dermatology.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Dermatology 52

The Pharma Data

AUGUST 19, 2021

7 Janssen has filed regulatory submissions for RYBREVANT TM with health authorities in Europe and other markets. entered into a license and collaboration agreement with Yuhan Corporation for the development of lazertinib. Dermatologic Adverse Reactions 7. 8] , [9] , [10] , [11] , [12]. 8] , [9] , [10] , [11] , [12]. **In

FDA Approval 52

FDA Approval Dermatology Genetics Development 52

Pharma Marketing Network

OCTOBER 27, 2020

Don ( PMN): Hello everyone welcome to the Pharma marketing podcast. Robin also coaches people who want to become thought leaders to drive their marketing, personal branding and career advancements. Robin welcome to the Pharma marketing podcast and thanks for joining us today. 009 – Robin Farmanfarmaian Podcast Transcript.

Insulin 52

Insulin Marketing Doctor Doctors 52

The Pharma Data

MAY 18, 2021

Our Crop Science Division achieved encouraging sales growth in an improved market environment. This business also expanded in Asia/Pacific as the market situation normalized following the previous year’s restrictions related to the COVID-19 pandemic. to 1.252 billion euros in a declining market. percent (Fx & portfolio adj.)

Sales 40

Sales Production Marketing Containment 40

The Pharma Data

APRIL 26, 2021

COVID-19 negatively impacted demand, particularly: dermatology, ophthalmology, the breast cancer portfolio, Sandoz Retail and Anti-Infectives. billion declined, mainly due to the USD 650 million upfront payment to in-license tislelizumab from BeiGene. Adakveo sales reached USD 37 million. Free cash flow¹ of USD 1.6

Sales 40

Sales Medicine Production Manufacturing 40

Pharma Marketing Network

OCTOBER 27, 2020

Don ( PMN): Hello everyone welcome to the Pharma marketing podcast. Robin also coaches people who want to become thought leaders to drive their marketing, personal branding and career advancements. Robin welcome to the Pharma marketing podcast and thanks for joining us today. 009 – Robin Farmanfarmaian Podcast Transcript.

Insulin 52

Insulin Doctor Doctors Marketing 52

XTalks

AUGUST 2, 2023

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98

Sales Manufacturing FDA Approval Life Science 98

The Pharma Data

SEPTEMBER 15, 2020

The results demonstrated that Penta immune responses were robust and noninferior to licensed meningococcal vaccines (MenB and MenACWY) in individuals 10-25 years of age, regardless of prior MenACWY exposure. A Phase 2 proof-of-concept study of Pfizer’s potential first-in-class pentavalent meningococcal vaccine candidate (Penta; MenABCWY).

Gene Therapy 52

Gene Therapy Vaccination Vaccine Trials 52

The Pharma Data

AUGUST 3, 2021

We expect that recovery in the dermatology segment will continue to progress over the coming quarters. Selling, General & Administrative (SG&A) expenses increased 7% driven by marketed product support due to increased customer engagement in response to the pandemic recovery and investment in new product launches. Tezepelumab.

Sales 52

Sales Production Antibody Development 52

Delveinsight

AUGUST 13, 2020

SAR440340 History: Regeneron and Sanofi are currently studying REGN3500 in respiratory and dermatological diseases where inflammation is thought to play an underlying role. Mometasone furoate is exclusively licensed to Novartis from a subsidiary of Merck & Co., for use in QVM149 (Worldwide excluding US).

Antibody 40

Antibody Medicine Trials Development 40